

Pharmasset Inc
Form 8-K
October 03, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 3, 2007

PHARMASSET, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction

of Incorporation)

001-33428
(Commission File Number)

98-0406340
(IRS Employer

Identification No.)

303-A College Road East

Princeton, NJ
(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (609) 613-4100

08540
(Zip Code)

(Former Name or Former Address, if Changed Since Last Report.)

Edgar Filing: Pharmasset Inc - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On October 3, 2007, Pharmasset, Inc. issued a press release announcing the commencement of dosing in a 28-day Phase 1 study of R7128 in combination with Pegasys® (pegylated interferon) plus Copegus® (ribavirin) in up to 75 treatment-naïve patients chronically infected with hepatitis C virus (HCV) genotype 1. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release dated October 3, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMASSET, INC.

Date: October 3, 2007

By: /s/ KURT LEUTZINGER

Name: Kurt Leutzinger

Title: Executive Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Press Release dated October 3, 2007.